The D1AMOND long-term safety extension study of ecopipam tablets in children, adolescents, and adults with Tourette’s Disorder

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children, adolescents and adults with Tourette’s Disorder (TD) who are eligible following their participation in studies EBS-101-TD-301, EBS-101-OL-001, or PSY-302A.

The study will consist of 21 study visits incorporating into 4 periods: a screening period, a baseline period (when patient will start titration to the full dose), a treatment period (when patient will take the full dose of study drug), and a follow-up period. The maximum duration of participation in the study will be approximately 2 years.